Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

410 Medical develops innovative resuscitation technologies for emergency and critical care.

view more →

AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics.

view more →

AtaCor Medical is developing next-generation cardiac rhythm management systems

view more →

Atsena Therapeutics is a clinical-stage gene therapy company focused on reversing or preventing blindness from inherited retinal diseases

view more →

Avivomed is a Minneapolis-based medical device company developing next-generation neuromodulation therapies

view more →

CREATE Medicines is a clinical-stage biotechnology company pioneering a new class of in vivo immune programming therapies

view more →

CVRx develops an implantable system that delivers baroreflex activation therapy. IPO in June 2021 (NASDAQ: CVRX).

view more →

GoCheck Kids provides a smartphone-based pediatric vision and hearing screening platform

view more →

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

view more →

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies to improve retinal blood flow and treat ischemia-driven eye diseases.

view more →

RapidPulse is a medical device company developing an innovative, minimally invasive vascular system for treating acute ischemic stroke.

view more →

SafeRide Health is a healthcare technology and services company that improves access to care by coordinating non-emergency medical transportation for vulnerable populations.

view more →

Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. IPO in October 2020 (NASDAQ: STTK)

view more →

Tune Therapeutics is a biotechnology innovator advancing a new class of epi-therapeutic medicines

view more →

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

view more →

Vigil Neuroscience is a clinical-stage biotechnology company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910